There have been several attempts to exploit TGF-β signaling inhibition as a therapeutic approach for malignant tumors, including the use of TGF-β receptor kinase inhibitors, TGF-β neutralizing antibodies, TGF-β antisense oligonucleotides (AONs), and siRNAs [27]. Here, TGFB1 is linked to cancer.